Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus

Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose‐lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta‐cell function in type 2 diabetes. Shorter disease duration...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilbrink, Francis J, Mudde, Aart H, Mulder, Alexandra H, Bhansing, Kavish J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031510/
https://www.ncbi.nlm.nih.gov/pubmed/29974671
http://dx.doi.org/10.1111/jdi.12857
_version_ 1783337326874722304
author Wilbrink, Francis J
Mudde, Aart H
Mulder, Alexandra H
Bhansing, Kavish J
author_facet Wilbrink, Francis J
Mudde, Aart H
Mulder, Alexandra H
Bhansing, Kavish J
author_sort Wilbrink, Francis J
collection PubMed
description Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose‐lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta‐cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20–4.76).[Image: see text]
format Online
Article
Text
id pubmed-6031510
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60315102018-07-11 Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus Wilbrink, Francis J Mudde, Aart H Mulder, Alexandra H Bhansing, Kavish J J Diabetes Investig Letters to the Editor Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose‐lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta‐cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20–4.76).[Image: see text] John Wiley and Sons Inc. 2018-07-04 2018-07 /pmc/articles/PMC6031510/ /pubmed/29974671 http://dx.doi.org/10.1111/jdi.12857 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Wilbrink, Francis J
Mudde, Aart H
Mulder, Alexandra H
Bhansing, Kavish J
Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
title Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
title_full Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
title_fullStr Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
title_full_unstemmed Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
title_short Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
title_sort disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031510/
https://www.ncbi.nlm.nih.gov/pubmed/29974671
http://dx.doi.org/10.1111/jdi.12857
work_keys_str_mv AT wilbrinkfrancisj diseasedurationasanindicatoroftheefficacyofliraglutideinpatientswithtype2diabetesmellitus
AT muddeaarth diseasedurationasanindicatoroftheefficacyofliraglutideinpatientswithtype2diabetesmellitus
AT mulderalexandrah diseasedurationasanindicatoroftheefficacyofliraglutideinpatientswithtype2diabetesmellitus
AT bhansingkavishj diseasedurationasanindicatoroftheefficacyofliraglutideinpatientswithtype2diabetesmellitus

Ejemplares similares